These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 23453616)

  • 1. Rapid selection of carbapenem-resistant Pseudomonas aeruginosa by clinical concentrations of ertapenem.
    Vainio S; van Doorn-Schepens M; Wilhelm A; Vandenbroucke-Grauls C; Murk JL; Debets-Ossenkopp Y
    Int J Antimicrob Agents; 2013 May; 41(5):492-4. PubMed ID: 23453616
    [No Abstract]   [Full Text] [Related]  

  • 2. Change in antipseudomonal carbapenem susceptibility in 25 hospitals across 9 years is not associated with the use of ertapenem.
    Eagye KJ; Nicolau DP
    J Antimicrob Chemother; 2011 Jun; 66(6):1392-5. PubMed ID: 21459897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carbapenem stewardship: does ertapenem affect Pseudomonas susceptibility to other carbapenems? A review of the evidence.
    Nicolau DP; Carmeli Y; Crank CW; Goff DA; Graber CJ; Lima AL; Goldstein EJ
    Int J Antimicrob Agents; 2012 Jan; 39(1):11-5. PubMed ID: 22047702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does ertepenem alter the susceptibility of Pseudomonas aeruginosa to carbapenems?
    Beović B; Kreft S; Seme K; Cizman M
    J Chemother; 2011 Aug; 23(4):216-20. PubMed ID: 21803699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IMP-1 metallo-beta-lactamase-producing Pseudomonas aeruginosa in a university hospital in the People's Republic of China.
    Wang CX; Mi ZH
    J Antimicrob Chemother; 2004 Dec; 54(6):1159-60. PubMed ID: 15537691
    [No Abstract]   [Full Text] [Related]  

  • 6. Association of ertapenem and antipseudomonal carbapenem usage and carbapenem resistance in Pseudomonas aeruginosa among 12 hospitals in Queensland, Australia.
    McDougall DA; Morton AP; Playford EG
    J Antimicrob Chemother; 2013 Feb; 68(2):457-60. PubMed ID: 23027714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic heterogeneity of carbapenem-resistant Pseudomonas aeruginosa isolates co-infecting the cerebrospinal fluid of a pediatric patient.
    Gaspar EB; Neves PR; Levy CE; Mamizuka EM; Lincopan N
    Diagn Microbiol Infect Dis; 2011 Aug; 70(4):568-70. PubMed ID: 21429695
    [No Abstract]   [Full Text] [Related]  

  • 8. Synergistic effects of fosfomycin and carbapenems against carbapenem-resistant Pseudomonas aeruginosa clinical isolates.
    Kunakonvichaya B; Thirapanmethee K; Khuntayaporn P; Montakantikul P; Chomnawang MT
    Int J Antimicrob Agents; 2015 May; 45(5):556-7. PubMed ID: 25724628
    [No Abstract]   [Full Text] [Related]  

  • 9. Emergence of carbapenem resistance in Pseudomonas aeruginosa isolates from a patient with cystic fibrosis in the absence of carbapenem therapy.
    Wolter DJ; Acquazzino D; Goering RV; Sammut P; Khalaf N; Hanson ND
    Clin Infect Dis; 2008 Jun; 46(12):e137-41. PubMed ID: 18462098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro Etest synergy of doripenem with amikacin, colistin, and levofloxacin against Pseudomonas aeruginosa with defined carbapenem resistance mechanisms as determined by the Etest method.
    He W; Kaniga K; Lynch AS; Flamm RK; Davies TA
    Diagn Microbiol Infect Dis; 2012 Dec; 74(4):417-9. PubMed ID: 22995366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Chinese hospitals.
    Wang J; Zhou JY; Qu TT; Shen P; Wei ZQ; Yu YS; Li LJ
    Int J Antimicrob Agents; 2010 May; 35(5):486-91. PubMed ID: 20185276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of group 1 versus group 2 carbapenems on imipenem-resistant Pseudomonas aeruginosa: an ecological study.
    Carmeli Y; Lidji SK; Shabtai E; Navon-Venezia S; Schwaber MJ
    Diagn Microbiol Infect Dis; 2011 Jul; 70(3):367-72. PubMed ID: 21683268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pseudomonas aeruginosa and beta-lactam antibiotics at the time of Europe].
    Cavallo JD; Mérens A
    Pathol Biol (Paris); 2008; 56(7-8):435-8. PubMed ID: 19019568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metallo-beta-lactamases produced by carbapenem-resistant Pseudomonas aeruginosa in Brazil.
    Viana Vieira V; Lourenço da Fonseca E; Paulo Vincente AC
    Clin Microbiol Infect; 2005 Nov; 11(11):937. PubMed ID: 16216114
    [No Abstract]   [Full Text] [Related]  

  • 15. Reduction in fluoroquinolone use following introduction of ertapenem into a hospital formulary is associated with improvement in susceptibility of Pseudomonas aeruginosa to group 2 carbapenems: a 10-year study.
    Cook PP; Gooch M; Rizzo S
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5597-601. PubMed ID: 21968357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative activity of beta-lactam agents (carbapenem excepted) against Pseudomonas aeruginosa strains with CARB or OXA beta-lactamases.
    Bert F; Branger C; Lambert-Zechovsky N
    Chemotherapy; 2004 Apr; 50(1):31-4. PubMed ID: 15084803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exposure to ertapenem is possibly associated with Pseudomonas aeruginosa antibiotic resistance.
    Cohen MJ; Block CS; Moses AE; Nir-Paz R
    Clin Microbiol Infect; 2014 Mar; 20(3):O188-96. PubMed ID: 24102767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KPC presence in Pseudomonas aeruginosa has minimal impact on the in vivo efficacy of carbapenem therapy.
    Hagihara M; Crandon JL; Urban CM; Nicolau DP
    Antimicrob Agents Chemother; 2013 Feb; 57(2):1086-8. PubMed ID: 23254422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absence of association between use of ertapenem and change in antipseudomonal carbapenem susceptibility rates in 25 hospitals.
    Eagye KJ; Nicolau DP
    Infect Control Hosp Epidemiol; 2010 May; 31(5):485-90. PubMed ID: 20334550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of fluoroquinolone and carbapenem susceptibilities in clinical isolates of levofloxacin-resistant Pseudomonas aeruginosa.
    Muramatsu H; Horii T; Takeshita A; Hashimoto H; Maekawa M
    Chemotherapy; 2005 May; 51(2-3):70-5. PubMed ID: 15870499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.